NCT01371045

Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs

Hormonal and Metabolic Responses to Oral Glucose During Somatostatin Analog Use

• Status: Withdrawn
• Phase: —
• Study type: Observational
• Enrollment: 0 (actual)
• Sponsor: Cedars-Sinai Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to test the effect of long-acting somatostatin analog medications, taken by patients with acromegaly or carcinoid syndrome, on growth hormone in comparison to healthy controls who are not receiving the medication in order to see whether or not the medication makes the oral glucose test less accurate. The Oral Glucose Tolerance Test (OGTT) is a standard test to measure growth hormone secretion. By comparing GH responses in non-acromegaly subjects taking somatostatin analog treatment, the relative contribution of the medication and the underlying disease state can be analyzed.

Detailed description

Subjects will be informed of the study and after providing written informed consent, subjects will be asked to undergo a 2-hour oral glucose tolerance test (ingestion of 75g glucose with subsequent timed assessment of growth hormone, glucose, insulin and related binding proteins.) Baseline assessment of hormones that may contribute to the results will be drawn, prior to performing the test. Patients will be asked to complete one visit total to participate in this trial.

Conditions

• Acromegaly

Interventions

Type	Name	Description
OTHER	Oral Glucose Tolerance Test (OGTT)	An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.

Timeline

• Start date: 2011-06-01
• Primary completion: 2019-06-01
• Completion: 2019-06-01
• First posted: 2011-06-10
• Last updated: 2025-02-13

Locations

1 site across 1 country: United States